FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200411569> ?p ?o ?g. }

• W4200411569 endingPage "11299" @default.
• W4200411569 startingPage "11285" @default.
• W4200411569 abstract "In recent years, biological therapies have revolutionized the management of inflammatory bowel disease (IBD); however, they are expensive. The development of biosimilar products has allowed us to reduce healthcare costs and improve patients' access to these treatments. Although various studies support the similarity between infliximab and its biosimilar CT-P13 in terms of efficacy and safety, there are unmet needs regarding research on these agents in the context of IBD.To analyze clinical response rates to CT-P13 and adverse events in IBD patients treated in real-life practice.An observational, prospective, multicenter study of IBD patients treated with CT-P13 in clinical practice who were naïve to biological treatments or failed to respond to other anti-tumor necrosis factor drugs or had switched from infliximab originator was carried out. No diagnostic or follow-up interventions were conducted on patients outside usual clinical practice. The primary endpoints were clinical response rates and number of adverse events. The primary efficacy variable was the proportion of patients who were in clinical remission and/or had a clinical response at 3, 6, 9, and 12 mo.A total of 220 IBD patients treated with CT-P13 (Remsima®) were included in the study: 87 (40%) with ulcerative colitis and 133 (60%) with Crohn's disease. Mean age of the patients was 41.47 (SD 15.74) years, and 58% were female. Nineteen (9%) patients started treatment with CT-P13 after switching from infliximab. Of the remaining 201 patients, 142 (65%) were naïve to biologic agents. At baseline, 68.6% (n = 138/201) of patients presented with active disease. After 12 mo of treatment, 14.8% (n = 12/81) presented with active disease, and 64.2% (n = 52/81) were in clinical remission without corticosteroids. After 3 mo, 75.5% (n = 115/152) had a clinical response or achieved clinical remission, which was sustained for 12 mo (85.2%; n = 69/81). There was a decrease in specific IBD indices at 3, 6, 9, and 12 mo (P < 0.001). A total of 34 adverse events were reported by 27 (12.3%) patients, 9 (26.5%) of which were serious.CT-P13 is an effective and safe infliximab biosimilar for the treatment of IBD in real-life practice and may be a valid and attractive alternative for the treatment of IBD." @default.
• W4200411569 created "2021-12-31" @default.
• W4200411569 creator A5006341310 @default.
• W4200411569 creator A5023730578 @default.
• W4200411569 creator A5042715991 @default.
• W4200411569 creator A5048579391 @default.
• W4200411569 creator A5048774215 @default.
• W4200411569 creator A5073600422 @default.
• W4200411569 creator A5088252642 @default.
• W4200411569 creator A5089647019 @default.
• W4200411569 date "2021-12-26" @default.
• W4200411569 modified "2023-10-18" @default.
• W4200411569 title "Real-world data on the infliximab biosimilar CT-P13 (Remsima^®) in inflammatory bowel disease" @default.
• W4200411569 cites W1251997985 @default.
• W4200411569 cites W1477056058 @default.
• W4200411569 cites W1827882046 @default.
• W4200411569 cites W1967570746 @default.
• W4200411569 cites W2009025779 @default.
• W4200411569 cites W2020350753 @default.
• W4200411569 cites W2039919901 @default.
• W4200411569 cites W2048543403 @default.
• W4200411569 cites W2056873984 @default.
• W4200411569 cites W2102013054 @default.
• W4200411569 cites W2105792933 @default.
• W4200411569 cites W2130173462 @default.
• W4200411569 cites W2142082253 @default.
• W4200411569 cites W2145436896 @default.
• W4200411569 cites W2169467558 @default.
• W4200411569 cites W2175886073 @default.
• W4200411569 cites W2198790708 @default.
• W4200411569 cites W2279977120 @default.
• W4200411569 cites W2308369648 @default.
• W4200411569 cites W2320720293 @default.
• W4200411569 cites W2523706394 @default.
• W4200411569 cites W2531216194 @default.
• W4200411569 cites W2560455300 @default.
• W4200411569 cites W2578994901 @default.
• W4200411569 cites W2586796756 @default.
• W4200411569 cites W2586976326 @default.
• W4200411569 cites W2587065878 @default.
• W4200411569 cites W2589358629 @default.
• W4200411569 cites W2613299853 @default.
• W4200411569 cites W2733544055 @default.
• W4200411569 cites W2734451106 @default.
• W4200411569 cites W2751387666 @default.
• W4200411569 cites W2754783592 @default.
• W4200411569 cites W2762105939 @default.
• W4200411569 cites W2794339583 @default.
• W4200411569 cites W2801351505 @default.
• W4200411569 cites W2801647441 @default.
• W4200411569 cites W2804564619 @default.
• W4200411569 cites W2896737472 @default.
• W4200411569 cites W2898518424 @default.
• W4200411569 cites W2923675504 @default.
• W4200411569 cites W2944309091 @default.
• W4200411569 cites W2980571487 @default.
• W4200411569 cites W3007969879 @default.
• W4200411569 cites W3022073735 @default.
• W4200411569 cites W4210662453 @default.
• W4200411569 cites W4211050664 @default.
• W4200411569 cites W4246739685 @default.
• W4200411569 cites W4292198229 @default.
• W4200411569 doi "https://doi.org/10.12998/wjcc.v9.i36.11285" @default.
• W4200411569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35071559" @default.
• W4200411569 hasPublicationYear "2021" @default.
• W4200411569 type Work @default.
• W4200411569 citedByCount "2" @default.
• W4200411569 countsByYear W42004115692022 @default.
• W4200411569 countsByYear W42004115692023 @default.
• W4200411569 crossrefType "journal-article" @default.
• W4200411569 hasAuthorship W4200411569A5006341310 @default.
• W4200411569 hasAuthorship W4200411569A5023730578 @default.
• W4200411569 hasAuthorship W4200411569A5042715991 @default.
• W4200411569 hasAuthorship W4200411569A5048579391 @default.
• W4200411569 hasAuthorship W4200411569A5048774215 @default.
• W4200411569 hasAuthorship W4200411569A5073600422 @default.
• W4200411569 hasAuthorship W4200411569A5088252642 @default.
• W4200411569 hasAuthorship W4200411569A5089647019 @default.
• W4200411569 hasBestOaLocation W42004115691 @default.
• W4200411569 hasConcept C126322002 @default.
• W4200411569 hasConcept C151730666 @default.
• W4200411569 hasConcept C197934379 @default.
• W4200411569 hasConcept C23131810 @default.
• W4200411569 hasConcept C2777138892 @default.
• W4200411569 hasConcept C2778260677 @default.
• W4200411569 hasConcept C2779134260 @default.
• W4200411569 hasConcept C2779280984 @default.
• W4200411569 hasConcept C2779343474 @default.
• W4200411569 hasConcept C2780479503 @default.
• W4200411569 hasConcept C535046627 @default.
• W4200411569 hasConcept C59491497 @default.
• W4200411569 hasConcept C71924100 @default.
• W4200411569 hasConcept C86803240 @default.
• W4200411569 hasConceptScore W4200411569C126322002 @default.
• W4200411569 hasConceptScore W4200411569C151730666 @default.
• W4200411569 hasConceptScore W4200411569C197934379 @default.
• W4200411569 hasConceptScore W4200411569C23131810 @default.
• W4200411569 hasConceptScore W4200411569C2777138892 @default.

• next